Country: Canada
Language: English
Source: Health Canada
ATAZANAVIR (ATAZANAVIR SULFATE)
BRISTOL-MYERS SQUIBB CANADA
J05AE08
ATAZANAVIR
150MG
CAPSULE
ATAZANAVIR (ATAZANAVIR SULFATE) 150MG
ORAL
60
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0149741002; AHFS:
CANCELLED POST MARKET
2022-04-28
_ _ _ _ _Page 1 of 77_ PRODUCT MONOGRAPH PR REYATAZ ® Atazanavir capsules 150, 200 and 300 mg (as atazanavir sulfate) Azapeptide Inhibitor of HIV-1 Protease Bristol-Myers Squibb Canada Co. Date of Preparation: Montreal, Canada December 3, 2003 Date of Revision: April 28, 2020 ® Registered trademark of Bristol-Myers Squibb Holdings Ireland used under licence by Bristol-Myers Squibb Canada Co. CONTROL NUMBER: 236039 _ _ _ _ _Page 2 of 77_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................22 DOSAGE AND ADMINISTRATION ..............................................................................39 OVERDOSAGE .................................................................................................................41 ACTION AND CLINICAL PHARMACOLOGY ............................................................42 STORAGE AND STABILITY ..........................................................................................46 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................47 PART II : SCIENTIFIC INFORMATION ...............................................................................48 PHARMACEUTICAL INFORMATION ..........................................................................48 CLINICAL TRIALS ........................................... Read the complete document